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ABSTRACT
Objective The Mediterranean diet has been promoted as 
a healthy dietary pattern, but whether the Mediterranean 
diet may help to prevent hepatic steatosis is not clear. 
This study aimed to evaluate the prospective association 
between adherence to the Mediterranean diet and risk of 
hepatic steatosis.
Design Population- based prospective cohort study.
Setting The Swiss CoLaus Study.
Participants We evaluated 2288 adults (65.4% women, 
aged 55.8±10.0 years) without hepatic steatosis at first 
follow- up in 2009–2012. Adherence to the Mediterranean 
diet was scaled as the Mediterranean diet score (MDS) 
based on the Mediterranean diet pyramid ascertained with 
responses to Food Frequency Questionnaires.
Outcome measures New onset of hepatic steatosis was 
ascertained by two indices separately: the Fatty Liver Index 
(FLI, ≥60 points) and the non- alcoholic fatty liver disease 
(NAFLD) score (≥−0.640 points). Prospective associations 
between adherence to the Mediterranean diet and risk of 
hepatic steatosis were quantified using Poisson regression.
Results During a mean 5.3 years of follow- up, hepatic 
steatosis was ascertained in 153 (6.7%) participants 
by FLI criteria and in 208 (9.1%) by NAFLD score. After 
multivariable adjustment, higher adherence to MDS was 
associated with lower risk of hepatic steatosis based 
on FLI: risk ratio 0.84 (95% CI 0.73 to 0.96) per 1 SD of 
MDS; 0.85 (0.73 to 0.99) adjusted for BMI; and 0.85 (0.71 
to 1.02) adjusted for both BMI and waist circumference. 
When using NAFLD score, no significant association was 
found between MDS and risk of hepatic steatosis (0.95 
(0.83 to 1.09)).
Conclusion A potential role of the Mediterranean diet in 
the prevention of hepatic steatosis is suggested by the 
inverse association observed between adherence to the 
Mediterranean diet and incidence of hepatic steatosis 
based on the FLI. The inconsistency of this association 
when hepatic steatosis was assessed by NAFLD 
score points to the need for accurate population- level 
assessment of fatty liver and its physiological markers.
INTRODUCTION
Hepatic steatosis is the most common cause 
of liver disease.1 In westernised countries, 
hepatic steatosis affects up to 34% of the 
general population and up to 74% of obese 
individuals, depending on the definition 
used.2–4 Hepatic steatosis—fat content of 
more than 5% of liver volume—is the first 
recognisable stage of non- alcoholic fatty liver 
disease (NAFLD).1 Hepatic steatosis, particu-
larly NAFLD, may progress to end- stage liver 
disease including fibrosis, cirrhosis and hepa-
tocellular carcinoma.5 Moreover, as hepatic 
steatosis increases the risk of metabolic 
syndrome, type 2 diabetes and cardiovascular 
disease (CVD), its prevention is of public 
health importance.6 An unhealthy dietary 
pattern remains one of the primary targets 
of lifestyle modification for the prevention 
and management of hepatic steatosis and 
NAFLD.7 8
The Mediterranean diet has been recently 
recommended for treatment of NAFLD.9 
In recent years, a growing body of evidence 
supports the idea that the Mediterranean 
diet may be the reference nutritional profile 
Strengths and limitations of this study
 ► This study had the benefit of a relatively large sam-
ple size and an average of 5.3 years of follow- up.
 ► We applied a definition of the Mediterranean diet that 
has been shown to be valid in a non- Mediterranean 
population.
 ► Our ascertainment of hepatic steatosis was based 
on two indices that have been validated for use in 
large epidemiological studies.
 ► We used dietary data measured only once at base-
line, and intraindividual variation over time might be 
present which may weaken the observed associ-
ations towards the null; however, dietary intake in 
CoLaus was relatively stable, suggesting that lack 
of repeated dietary measures is unlikely to alter our 
findings substantially.
 ► The precision of the two hepatic steatosis indices 
used is different and may be influenced by the pres-
ence of steatohepatitis or advanced liver fibrosis.
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for the prevention of hepatic steatosis development.10–12 
Adherence to the Mediterranean diet has been reported 
to have a beneficial impact on risks of CVD,13 14 type 2 
diabetes15 and metabolic syndrome.16 Trial evidence 
demonstrated the potential benefits of the Mediterra-
nean diet against progress of hepatic steatosis focusing 
on individuals with existing hepatic steatosis, either 
alone17–22 or associated with metabolic risk factors such 
as obesity or diabetes.22–25 Research among those without 
clinically manifest hepatic steatosis is restricted to obser-
vational evidence, reporting an inverse association that 
greater adherence to a Mediterranean diet is associated 
with lower prevalence of hepatic steatosis.26 27 However, 
the cross- sectional design of these studies limits infer-
ence for causal associations and can be used mainly for 
hypothesis generation. Relevant longitudinal evidence 
for the primary prevention of hepatic steatosis or NAFLD 
has been reported only by the Framingham Heart Study, 
with a significant inverse association of adherence to the 
Mediterranean diet with risk of hepatic steatosis in 1521 
adults over 6 years of follow- up,28 but evidence is lacking 
in Europe.
Given the limited evidence from population- based 
epidemiological studies thus far, we aimed to investigate 
the prospective association between adherence to the 
Mediterranean diet and the risk of developing hepatic 
steatosis among adults without clinically manifest hepatic 
steatosis. We hypothesised that greater adherence to the 




We evaluated participants in the CoLaus Study, an 
ongoing population- based cohort investigating the clin-
ical, biological and genetic determinants of CVD in the 
city of Lausanne, Switzerland.29 Inclusion criteria of the 
recruitment were adults of European origin, aged 35–75 
years.29 There were three study phases: baseline recruit-
ment in 2003–2006 (n=6733), the first follow- up in 2009–
2012 (n=5064) and the second follow- up in 2014–2017 
(n=4881). We conducted dietary assessment at the first 
follow- up and therefore considered the first follow- up as 
the study baseline. Fatty Liver Index (FLI) and NAFLD 
score, two indices of hepatic steatosis, were available at 
baseline.27 If participants met the joint criterion of FLI 
≥60 or NAFLD score ≥−0.640 at baseline, we excluded 
them as prevalent cases (see below) (n=2036). We also 
excluded participants with missing information on diet, 
outcome and covariates (n=740) (online supplemental 
figure S1).
Patient and public involvement
Patients and/or the public were not involved in the 
design, conduct, reporting or dissemination plans of this 
research.
Dietary assessment
Participants completed a self- administered, 97- item, semi-
quantitative Food Frequency Questionnaire (FFQ) about 
their habitual dietary intake over the last 4 weeks,30 the 
validity of which had been assessed in canton Geneva 
against 24- hour recalls.30 31 For each item, participants 
were instructed to report consumption frequencies by 
selecting one of the seven frequency options from ‘less 
than once during the last 4 weeks’ to ‘two or more times 
per day’ and by selecting a usual serving size (smaller, 
equal or bigger to a reference size).
Mediterranean diet scores
We derived the pyramid- based Mediterranean diet score 
(MDS) as a measure of adherence to the Mediterranean 
diet from responses to the FFQ as we conducted previ-
ously.27 This MDS is based on the Mediterranean dietary 
pyramid proposed by the Mediterranean Diet Foundation 
for both Mediterranean and non- Mediterranean coun-
tries, and accounting for the traditional Mediterranean 
diet, contemporary lifestyle and food environment.32 We 
have previously reported that this MDS scoring algorithm 
predicted CVD incidence,33 as well as the prevalence of 
hepatic steatosis27 in non- Mediterranean populations. 
Briefly, a continuous score of 0–1 was assigned for each 
recommended level of the 15 components of the pyramid 
(vegetables, legumes and fish as healthy items; red meat, 
processed meat, potato and sweets as unhealthy items; 
and fruits, nuts, cereals, eggs, dairy, white meat and alco-
holic beverages as items for which moderate consumption 
was recommended). The resulting MDS ranges between 
0 and 15 on a continuous scale. The MDS calculation 
was adjusted to an energy intake of 2000 kcal/d (8.37 
MJ/day) by applying a regression- residual technique for 
energy adjustment to each food group variable.33 34
Ascertainment of hepatic steatosis
Two indices of hepatic steatosis were evaluated: FLI35 and 
NAFLD liver fat score.36 FLI was calculated based on a 
logistic function including body mass index (BMI), waist 
circumference, fasting triglycerides and gamma- glutamyl 
transferase (GGT) levels as follows:
FLI=1/(1+e−(0.953×ln (triglycerides)+0.139×BMI+0.718×ln 
(GGT)+0.053×waist circumference−15.745)).
FLI×100 ranges from 0 to 100. Presence of hepatic 
steatosis was defined by FLI ≥60, a value with a sensitivity 
of 61% and a specificity of 86%.35 FLI was tested previ-
ously in comparison to ultrasonography with an area 
under the receiver operating characteristic curve of 0.78 
(OR 95% CI: 0.77 to 0.83).37
The NAFLD score was calculated based on an algo-
rithm including a logistic function with the presence of 
metabolic syndrome defined by criteria of International 
Diabetes Federation,38 presence of type 2 diabetes, and 
fasting concentrations of insulin, aspartate aminotrans-
ferase (AST) and the AST/alanine transaminase (ALT) 
ratio:
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NAFLD score=−2.89+1.18×metabolic syndrome (yes/
no)+0.45×type 2 diabetes (yes/no)+0.15×fasting insulin 
(mU/L)+0.04×fasting AST (U/L)−0.94×AST/ALT.
Presence of hepatic steatosis was defined by a NAFLD 
score ≥−0.640, a value with a sensitivity of 86% and a spec-
ificity of 71%, when compared with proton MRI.36
Assessment of covariates at baseline
Sociodemographic, lifestyle and health characteristics 
were collected by self- administered questionnaires. Age, 
sex, marital status, occupational status and educational 
level were included as indicators of sociodemographic 
condition. Smoking status was classified as ‘never’, 
‘former’ and ‘current’. Alcohol consumption was assessed 
by the number of alcoholic beverage units consumed in 
the past week and further categorised as ‘abstainers’ (0 
unit/week), ‘moderate’ (1–21 units/week for men, 1–14 
for women) and ‘heavy’ (>21 units/week for men, >14 for 
women) drinkers (1 unit corresponds to 8 g of alcohol). 
Physical activity was assessed with a self- administered 
quantitative physical activity frequency questionnaire.39 
Health characteristics included presence of metabolic 
syndrome and family history of diabetes. Anthropo-
metric and blood pressure measurements were obtained 
using standard procedures and equipment as previously 
described.29 Plasma triglycerides, high- density lipopro-
tein cholesterol and glucose were measured using stan-
dard enzymatic methods, and ALT, AST and GGT were 
measured using reference methods as standardised by the 
International Federation of Clinical Chemistry.
Statistical analysis
Statistical analyses were performed using Stata (V.15; 
StataCorp, College Station, Texas, USA) with a two- sided 
test with α=0.05. Descriptive statistics were obtained in 
the participants included in this study in comparison with 
those excluded from this study. Cohen’s kappa statistics 
were calculated to assess the agreement between the FLI 
and NAFLD score.
MDS, as a measure of adherence to the Mediterra-
nean diet, was evaluated both categorically (quintiles) 
and continuously scaled as 1 SD unit. The association of 
MDS with the risk of hepatic steatosis was assessed using 
multivariable- adjusted Poisson regression models with 
robust SEs and estimating risk ratios (RRs) and 95% CIs. 
Models were adjusted for age, sex, marital status, occu-
pational status, educational level, smoking status, energy 
intake, total energy expenditure and date of dietary assess-
ment (to adjust for seasonality). We further adjusted for 
BMI and waist circumference as potential confounders or 
factors on the causal pathway to assess the possible impact 
of overall and central adiposity on the association of the 
Mediterranean diet and hepatic steatosis.
Additionally, we also adjusted for changes in BMI catego-
ries between baseline and follow- up; for alcohol consump-
tion (units/week); for clinical variables of metabolic risk 
(blood pressure >130/85 mm Hg (yes/no), triglycerides 
>1.7 mmol/L (yes/no), high- density lipoprotein level 
<1.29 mmol/L for men and <1.03 mmol/L for women 
(yes/no), and glucose level ≥5.6 mmol/L (yes/no))38; 
and for family history of diabetes and metabolic syndrome 
(only for FLI) to examine their influence on the associa-
tion of interest.
Possible interactions between MDS and age, sex, BMI 
and alcohol consumption were tested using the Wald test. 
Several sensitivity analyses were conducted to examine 
the robustness of the observed findings. First, to assess the 
role of alcohol consumption (as alcohol is a risk factor for 
fatty liver accumulation), we excluded the alcohol compo-
nent from the MDS, while adjusting for alcohol consump-
tion as a covariate. We took the same approaches for 
the other MDS components to assess the impact of each 
component on the observed associations. Second, we 
conducted separate analyses after excluding participants 
with BMI ≥30 kg/m2; implausible energy intake (<500 or 
>3500 kcal/day in women and <800 or >4000 kcal/day in 
men); excessive alcohol consumption; prevalent diabetes 
(defined as glycated haemoglobin ≥48 mmol/mol, or 
fasting plasma glucose ≥7.0 mmol/L, or use of hypogly-
caemic drugs or insulin); or probable secondary causes 
of hepatic steatosis such as hepatitis B or C, HIV, hepato-
toxic or autoimmune disease medications. We evaluated 
the robustness of the results to an alternative definition 
of prevalent hepatic steatosis. While we excluded partici-
pants with prevalent hepatic steatosis using the specified 
cut- offs of FLI or NAFLD score in the primary analysis, we 
used each of the two indices separately in sensitivity anal-
yses, whereby we evaluated 2652 adults in longitudinal 
analysis based on FLI; and 2568 adults, based on NAFLD. 
Finally, we used more restrictive cut- points and excluded 
participants with NAFLD score ≥−0.640 or with FLI>30.
In a post- hoc analysis, due to inconsistency of the asso-
ciations observed for FLI and NAFLD score, we also calcu-
lated the Hepatic Steatosis Index (HSI)40 based on the 
ratio of AST/ALT, BMI, presence of type 2 diabetes and 
sex:
HSI=8×AST/ALT+BMI+2 (presence of diabetes)+2 (if 
women).
Presence of hepatic steatosis was defined by an HSI 
>36. After excluding participants with HSI >36 at baseline 
(n=2674), we evaluated 2351 adults.
In a post- hoc analysis pertaining to sensitivity of the 
results to model covariates and for better understanding 
of potential mechanisms, longitudinal associations of 
MDS with follow- up measures of log- transformed GGT, 
ALT and AST levels, and with changes in BMI and waist 
circumference from baseline to follow- up were examined 
using multivariable- adjusted linear regression. These 
results were expressed as β coefficient (95% CIs) for 
changes in each measure per 1 SD difference in MDS.
RESULTS
Participant characteristics
Of the initial 5064 participants, 2776 (54.8%) were 
excluded, leaving 2288 participants (65.4% women; 
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55.8±10.0 years) for analysis. Participants included were 
more likely to be women, show higher sociodemographic 
characteristics and lower BMI, waist circumference, liver 
enzymes or prevalence of metabolic syndrome in compar-
ison with excluded individuals (online supplemental 
table S1). Being in the highest quintile of MDS was higher 
among women compared with men, positively correlated 
with sociodemographic characteristics, and negatively 
correlated with being current smokers, heavy alcohol 
drinkers, and with BMI, waist circumference, GGT and 
TG (table 1).
Adherence to the Mediterranean diet and risk of hepatic 
steatosis
After a mean 5.3 (SD: 0.5) years of follow- up, there were 
153 (6.7%) and 208 (9.1%) participants with hepatic 
steatosis based on FLI and NAFLD score, respectively 
(online supplemental table S2). Case identification 
by FLI and NAFLD score was modestly concordant 
(kappa=0.60).
Multivariable- adjusted analysis showed an inverse 
association between MDS quintiles and risk of hepatic 
steatosis based on FLI (ptrend <0.006) with RR (95% CI) 
comparing the top to the bottom category of 0.50 (0.28 
to 0.91). The inverse associations across quintiles of MDS 
weakened after adjustment for BMI (ptrend=0.031) or both 
BMI and waist circumference (ptrend=0.034) (table 2): 
RR (95% CI)=0.61 (0.34 to 1.09) and 0.60 (0.34 to 1.08), 
respectively. In analyses using MDS as a continuous vari-
able, the inverse association with risk of hepatic steatosis 
based on FLI (0.84 (0.73 to 0.96) per 1 SD of MDS) 
remained unchanged but getting imprecise after adjust-
ment for BMI (0.85 (0.73 to 0.99)) and adjustment for 
both BMI and waist circumference (0.85 (0.71 to 1.02)). 
In sensitivity analysis, the magnitude of the inverse associ-
ations changed a little after further adjustment for alcohol 
consumption, presence of metabolic syndrome, changes 
in BMI categories or clinical variables (medication use or 
prevalent diseases), while adjustment for BMI and clinical 
variables increased SEs (online supplemental table S3).
Conversely, there was no association between MDS 
and the risk of hepatic steatosis defined by NAFLD score 
criteria, with RRs (95% CIs) ranging from 0.93 (0.82 
to 1.05) to 1.00 (0.86 to 1.17) over different regression 
models (table 2 and online supplemental table S3).
Interaction and sensitivity analyses
No significant interactions were found between MDS 
and age, sex, BMI or alcohol consumption on risk of 
hepatic steatosis (pinteraction >0.05; results not shown). The 
contribution of each component of the MDS on risk of 
hepatic steatosis was assessed by sequential subtraction 
of components from the score (figure 1). Excluding the 
components of the MDS did not substantially affect the 
inverse associations with hepatic steatosis based on FLI; 
the magnitude of the associations remained reasonably 
stable, but it became weaker (p>0.05) after excluding 
fruits, cereals, dairy products, red or processed meat, or 
alcohol.
In sensitivity analyses, when excluding the alcohol 
component from the MDS but adjusting for alcohol 
consumption as a covariate, the inverse associations 
between MDS and risk of hepatic steatosis based on FLI 
became weaker (online supplemental table S4). The 
primary results were not different when excluding partic-
ipants with BMI ≥30 kg/m2, excessive alcohol consump-
tion or secondary causes of hepatic steatosis (online 
supplemental table S4). Excluding participants with 
implausible energy intakes weakened the associations 
(online supplemental table S4). The analysis of an alter-
native definition of prevalent hepatic steatosis, excluding 
participants with only high FLI score at baseline, did not 
alter the significant inverse association between MDS and 
risk of FLI- based hepatic steatosis (online supplemental 
table S5). In post- hoc analyses, there was an inverse associ-
ation between MDS quintiles and risk of hepatic steatosis 
based on HSI (ptrend=0.070) with RR (95% CI) comparing 
the top with the bottom category of 0.70 (0.55 to 0.91); 
a significant inverse association with HSI was observed 
per 1 SD increase in MDS (0.90 (0.82 to 0.98)) (online 
supplemental table S5). Effect sizes were of slightly 
higher magnitude when excluding those with FLI >30 or 
NAFLD score ≥−0.640 at baseline, but CIs were wider due 
to smaller sample size (online supplemental table S6).
For NAFLD score, no significant associations were found 
in any of the sensitivity analyses (online supplemental 
tables S4 and S5). The sole exception was when partici-
pants with a high NAFLD score at baseline were excluded, 
where an inverse association between MDS quintiles and 
risk of hepatic steatosis was present (ptrend=0.039), but this 
association was attenuated to the null after adjustment for 
BMI (online supplemental table S5).
Longitudinal analyses for adiposity and markers of hepatic 
function
In post- hoc exploratory analyses, there were inverse asso-
ciations of MDS with changes in BMI (β coefficient (95% 
CIs) per 1 SD higher MDS of −0.08 (–0.15 to –0.02)) and 
in waist circumference (−0.33 (–0.61 to –0.06)) (online 
supplemental table S7). For the markers of hepatic func-
tion, MDS showed a trend toward inverse association with 
GGT levels (ptrend=0.047) (β coefficient (95% CIs) per 1 
SD higher MDS of −1.66 (–3.73 to 0.41)), but not with 
ALT or AST levels (online supplemental table S8).
DISCUSSION
In this first population- based European study among 
adults free from clinically manifest hepatic steatosis to 
report on the prospective association between adherence 
to the Mediterranean diet and risk of hepatic steatosis, 
we found an inverse association between MDS and risk 
of hepatic steatosis based on FLI criteria. This relation-
ship was attenuated to the null when controlled for 
general and central adiposity assessed by the BMI and 
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Table 1 Baseline characteristics of participants according to quintiles of the Mediterranean diet score, CoLaus Study, 
Switzerland (n=2288)
Characteristic
               Quintiles of Mediterranean diet score*
P value*
Q1 Q2 Q3 Q4 Q5
(n=458) (n=458) (n=457) (n=458) (n=457)
Age (years) 57.1±10.6 56.7±9.9 56.4±10.5 55±9.8 53.7±8.9 <0.001
Women (%) 59.0 62.9 67.6 66.6 71.1 0.001
Marital status (%) 0.51
  Single 17.7 14.2 16.8 17.5 16.4
  Married/cohabitant 53.9 55.7 59.1 57.2 57.3
  Widowed/separated/divorced 28.4 30.1 24.1 25.3 26.3
Employed (%) 57.9 60.3 59.1 68.3 72.0 <0.001
Education (%)
  University 19.2 21.6 26.0 31.7 31.1
  High school 26.4 28.2 28.4 29.7 29.5
  Apprenticeship 39.3 35.2 34.8 28.2 28.4
  Mandatory education 15.1 15.1 10.7 10.5 10.9 <0.001
Current smokers (%) 24.7 21.8 22.3 16.2 15.5 0.014
Alcohol intake (%)†
  Abstainers 21.8 24.0 25.8 24.7 21.2
  Moderate 63.8 66.2 69.4 70.7 76.6
  Heavy 14.4 9.8 4.8 4.6 2.2 <0.001
Total energy intake (kcal/day) 1819±705 1812±675 1781±729 1821±653 1801±595 0.87
Protein (% energy) 15.8±3.3 15.9±4.1 15.3±3.0 15.2±3.0 14.7±2.6 <0.001
Carbohydrates (% energy) 45.3±9.2 45.9±9.1 47.3±8.0 47.6±8.2 49.0±7.8 <0.001
Fat (% energy) 33.6±6.5 34.5±6.9 34.6±6.7 34.5±6.5 34.1±6.9 0.11
TEE (kcal/day) 2562±589 2600±618 2564±602 2558±555 2589±565 0.84
Metabolic syndrome (%)‡ 11.8 9.8 12.3 12.7 7.4 0.063
BMI (kg/m2) 24.0±2.7 23.8±2.9 23.9±3.0 23.6±2.8 23.3±2.7 0.003
Waist circumference (cm) 85.4±8.5 84.9±9.4 85.0±9.2 84.0±8.7 82.9±8.6 <0.001
Triglycerides (mmol/L) 1.1±0.5 1.0±0.5 1.1±0.5 1.0±0.5 1.0±0.5
  Median (IQR) 1.0 (0.8–1.3) 0.9 (0.7–1.2) 1.0 (0.7–1.3) 0.9 (0.7–1.2) 0.9 (0.7–1.2) 0.009
GGT (U/L) 25.0±16.5 25.1±17.9 23.2±14.5 24.0±17.9 21.5±12.1 0.002
  Median (IQR) 20 (15–29) 21 (15–28) 19 (14–28) 19 (14–26) 18 (14–25)
  ≥50 (%) 7.4 6.3 5.7 6.1 2.6 0.025
ALT (U/L) 21.3±7.8 22.1±8.9 22.5±9.7 21.3±8.7 21.5±8.7 0.12
  Median (IQR) 19 (16–25) 20 (16–26) 20 (16–27) 19 (16–25) 20 (16–24)
  ≥40 (%) 3.5 5.4 8.3 4.6 3.5 0.005
AST (U/L) 26.0±5.85 26.2±6.5 26.1±6.6 25.8±6.1 25.7±5.7 0.68
  Median (IQR) 25 (22–29) 25 (22–29) 25 (21–29) 25 (22–29) 25 (22–29)
  ≥37 (%) 4.1 8.3 6.3 5.0 4.4 0.038
Data are mean ± SD for continuous variables or percent for categorical variables, unless otherwise stated.
*The population was divided into five groups by quintiles (Q1–Q5) of the Mediterranean diet score. P values were computed by using ANOVA for 
continuous variables and Χ2 test for categorical variables.
†Alcohol consumption categorised as ‘abstainers’ (0 unit/week), ‘moderate’ (1–21 units/week for men, 1–14 for women) and ‘heavy drinkers’ (>21 
units/week for men, >14 for women).
‡Metabolic syndrome defined according to the International Diabetes Federation (waist circumference ≥94 cm in men and ≥80 cm in women plus at 
least two of the following factors: serum triglycerides ≥1.70 mmol/L or specific treatment for this lipid abnormality; serum high- density lipoprotein 
cholesterol <1.03 mmol/L in men and <1.29 mmol/L in women or specific treatment for this lipid abnormality; systolic blood pressure ≥130 mm Hg 
or diastolic blood pressure ≥85 mm Hg or treatment for previously diagnosed hypertension; and fasting plasma glucose ≥5.6 mmol/L or previously 
diagnosed type 2 diabetes).
ALT, alanine aminotransferase; ANOVA, analysis of variance; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma- glutamyl 
transferase; IQR, interquartile range; TEE, total energy expenditure.
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waist circumference. In contrast, there was no association 
between adherence to the Mediterranean diet and risk of 
hepatic steatosis based on NAFLD score criteria.
Current findings in context of other evidence
Our finding based on FLI is consistent with the only 
published prospective study relating the Mediterranean 
diet to hepatic steatosis, where each SD increase in MDS 
was estimated to decrease the odds for incident hepatic 
steatosis by 26% (95% CI 10% to 39%).28 By contrast, the 
point estimate of the effect size in our study was smaller 
(16% (95% CI 4% to 27%)). A possible explanation partly 
lies in methodological differences. We used biochemical 
and anthropometric markers to estimate hepatic steatosis 
in the current study, while the previous study used CT 
assessment.
No association was found between adherence to the 
Mediterranean diet and risk of hepatic steatosis based on 
the NAFLD score. For possible explanations based on the 
differences in their components, the FLI includes GGT, 
while NAFLD score includes AST and AST/ALT ratio; the 
FLI includes adiposity markers, while the NAFLD score 
does not; the FLI includes a lipid marker (triglycerides) 
while NAFLD score includes markers of glycaemic 
status. Previous studies showed a modest association 
of GGT and ALT (but not AST) with the prevalence of 
hepatic steatosis.1 Indeed, our analysis showed an inverse 
Figure 1 Prospective association of the Mediterranean diet score (MDS) with the risk of hepatic steatosis, CoLaus Study, 
Switzerland (n=2288): sensitivity analysis to examine influence of each component of Mediterranean diet. Statistical analysis 
using Poisson regression with robust SEs; results are expressed as risk ratios (RRs) and 95% CIs. RRs and 95% CIs were 
estimated per 1 SD of MDS (overall association) or of each MDS computed after excluding one component. *Adjusted for age 
(years), sex, marital status (single, married/cohabiting and widowed/separated/divorced), occupational status (working and not 
working), education level (university, high school, apprenticeship and mandatory education), smoking status (never, former and 
current), energy intake (kcal/day), total energy expenditure (kcal/day) and date of dietary assessment. FLI, Fatty Liver Index; 
NAFLD, non- alcoholic fatty liver disease.
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association between MDS and GGT levels, but not with 
AST or ALT, and these findings could explain the discrep-
ancy between the two indices. Notably, our sensitivity 
analyses using different definitions of hepatic steatosis 
showed an inverse association between MDS quintiles 
and risk of hepatic steatosis based on NAFLD score after 
excluding participants with high baseline NAFLD score 
only. This could be explained by modest concordance 
between the two measures. Of note, there were no statis-
tically significant associations between MDS and risk of 
hepatic steatosis based on FLI after excluding partici-
pants with FLI >30 at baseline, which led to a smaller 
sample size and consequently a lower statistical power 
in our study. In a post- hoc analysis, we found an inverse 
association between adherence to the Mediterranean 
diet and hepatic steatosis as assessed by HSI, an alterna-
tive score to detect hepatic steatosis. Although case iden-
tification by HSI and FLI (kappa=0.27) or NAFLD score 
(kappa=0.18) was weakly concordant, our finding based 
on FLI is consistent with HSI. This could be explained 
potentially by BMI as one of the components of both FLI 
and HSI, highlighting the importance of obesity for inci-
dent hepatic steatosis.41
The inverse association between MDS and risk of 
hepatic steatosis defined by FLI remained significant 
after adjusting for BMI only, but became imprecise and 
not significant after adjusting for both BMI and waist 
circumference or for changes in BMI over the follow- up 
period. These results suggest the collinearity between 
the central adiposity and hepatic steatosis as the central 
adiposity may partly reflect hepatic steatosis. This biolog-
ically plausible finding is in agreement with previous 
cross- sectional findings for MDS and prevalent hepatic 
steatosis in CoLaus Study and the British Fenland Study 
we reported,27 and a study in Hong Kong.42 Our finding 
that the MDS was negatively associated with an increase in 
BMI after 5.3 years of follow- up is consistent with the find-
ings from the Framingham Heart Study which observed 
the same trend over 6- year follow- up,28 and from Nurses’ 
Health Study and Health Professionals’ Follow- up Study 
evaluating 20- year longitudinal data with repeated self- 
reported measures of diet and adiposity measures.43
Sequential subtraction of different components of the MDS 
showed that fruits, cereals, dairy products, red or processed 
meat, or alcohol partially accounted for the observed asso-
ciation. These findings agree with previous studies26 28 44 45 
including the Framingham Heart Study suggesting benefits 
of low consumption of red meat and high consumption of 
fruits or whole grains28; and a cross- sectional analysis from the 
PREDIMED Study suggesting the benefit of low consumption 
of red meat.26 Moreover, the Mediterranean diet is charac-
terised by a moderate- to- high consumption of whole grains, 
which has been inversely associated with the likelihood of 
having NAFLD.46
Possible mechanisms and implications
Hepatic steatosis is associated with a number of meta-
bolic risk factors including insulin resistance, type 2 
diabetes, dyslipidaemia, metabolic syndrome and oxida-
tive stress.47 Mediterranean diet- associated phenolic 
compounds (phenolic acids and polyphenols) found in 
fruits and vegetables and high levels of monounsaturated 
fatty acids of olive oil have been shown to inhibit de novo 
lipogenesis, improve peripheral insulin sensitivity, and 
reduced cardiovascular risk mainly due to their antiox-
idant, anti- inflammatory and anti- fibrotic effects.18 48–51 
Moreover, different components of the Mediterranean 
diet, including omega-3 polyunsaturated fatty acids 
(PUFA), fibre and antioxidant rich- foods are inversely 
associated with hepatic steatosis.52 53 One meta- analysis of 
interventional studies reported that omega-3 PUFA were 
negatively associated with hepatic steatosis.54 The Medi-
terranean diet is also low in saturated fat, which has been 
demonstrated to increase hepatic triglycerides content 
and hepatic insulin resistance.55 56 Finally, the high- fibre 
content of the Mediterranean diet has been associated 
with reduced hepatic fat.18 52
Hepatic steatosis is associated with cardiometabolic 
diseases and substantially impacts public health.13 15 16 
Thus, our finding of an inverse association between adher-
ence to the Mediterranean diet and risk of hepatic 
steatosis would support the importance of dietary advice 
for the prevention of hepatic steatosis as well as its treat-
ment. However, future work should confirm whether or 
not the clinical importance of the Mediterranean diet 
for the prevention of hepatic steatosis is independent of 
obesity or central adiposity.
Strengths and limitations
To our knowledge, this is the first European prospective 
study assessing the association between the Mediterra-
nean diet and risk of hepatic steatosis. The study had the 
benefit of a relatively large sample size and an average 
of 5.3 years of follow- up, and applied a definition of the 
Mediterranean diet that has been shown to be valid in a 
non- Mediterranean population.33
Several limitations of this study merit consideration. 
Measurement error and recall bias are inevitable when 
using self- reported dietary instruments, limiting the ability 
to precisely measure adherence to the Mediterranean diet, 
although adjustment for energy intake may have reduced 
the magnitude of measurement error.57 We used diet data 
measured only at baseline but recognised that intraindi-
vidual variation over time might be present which would be 
expected to weaken the observed associations, and hence our 
findings may be biased towards the null. However, in CoLaus, 
average change in estimated total energy intake from first 
to second follow- up was 51 kcal/day and changes for each 
macronutrient (expressed as % of total energy intake) were 
about 1% (data not shown). Thus, dietary intake in CoLaus 
was relatively stable, suggesting that the lack of availability 
of repeat dietary measures is unlikely to alter our findings 
substantially.
Our ascertainment of hepatic steatosis was based on two 
indices, but not on liver biopsy or direct imaging assess-
ment; hence, information bias (misdiagnosis) cannot be 
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ruled out. Although liver biopsy is the gold standard for 
diagnosing hepatic steatosis, its use in apparently healthy 
participants would be unethical and unfeasible in a large 
population- based study. Further, previous studies have 
shown that FLI and NAFLD score can accurately identify 
hepatic steatosis with good sensitivity and specificity, and 
these scores have been validated for use in large epide-
miological studies.36 37 58 59 But, although both FLI and 
NAFLD score can indicate hepatic steatosis, their preci-
sion is variable.60 Moreover, presence of steatohepatitis or 
advanced liver fibrosis could influence the relationship of 
FLI or NAFLD score with hepatic steatosis.61 Of note, our 
study was not designed to assess the role of adherence to 
the Mediterranean diet in hepatic fibrosis.
Although we adjusted for many relevant confounders 
and performed a series of sensitivity analyses, we cannot 
rule out residual confounding due to unmeasured vari-
ables or covariates measured with error. On the other 
hand, our adjustment for BMI and waist circumference 
as markers of general and central adiposity may poten-
tially be an overadjustment if adiposity is on the causal 
pathway between dietary adherence and hepatic steatosis. 
However, since FLI may approximate hepatic steatosis 
with a degree of imprecision, adjusting for adiposity in 
these analyses may not represent adjusting the associa-
tion between diet and steatosis directly, but through an 
HSI that already includes adiposity measures in its defi-
nition. Nevertheless, our analytical approach is compre-
hensive, showing the results for crude analyses, followed 
by multivariable adjustment without and with further 
adjustment for adiposity markers. Future research with 
repeat measurements should further investigate this 
issue. Generalisability of our findings is limited because 
included participants seemed to be healthier than those 
excluded, and our findings were obtained in a single 
European population. Still, they confirm the findings 
from a previous prospective study conducted in the USA28 
and might serve as a reference for other studies.
CONCLUSION
Adherence to the Mediterranean diet was inversely asso-
ciated with risk of hepatic steatosis based on the FLI, 
and the association was independent of several known 
risk factors. Conversely, the association was not observed 
when using different criteria specifying the NAFLD score. 
These findings support recommendations on following 
the Mediterranean diet for hepatic steatosis prevention in 
addition to the existing evidence for its benefit for CVD 
prevention. Nonetheless, the findings also highlight the 
need for further research with more accurate measures 
of hepatic steatosis to replicate these findings in different 
populations and settings.
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